St. Jude Medical Inc.
) revealed another positive study results data presented at Heart
Rhythm 2014 - the Heart Rhythm Society's Annual Scientific
Sessions. The data revealed that the use of St. Jude's Medical
Quartet Quadripolar LV lead lowered the number of hospitalizations
by 53% compared to patients in the non-quadripolar group.
The lower hospitalization rate translated into a statistically
significant 62% reduction in overall costs for both health care
systems and patients. The data also showed that the patients using
the St. Jude's quadripolar lead had a 98% probability of having
lower costs than patients with non-quadripolar leads.
Following the breakout of this data, shares of the company climbed
1.4% till the last closing date.
The study focused on two types of hospitalizations - heart failure
and LV lead surgical revision. It involved 198 patients over three
years, implanted with either a St. Jude Medical Quartet Quadripolar
LV lead or a non-quadripolar LV lead.
Recently, St. Jude Medical also revealed that according to data
presented at Late Breaking Clinical Trial Session during Heart
Rhythm 2014, patients adhering to St. Jude Medical Merlin Remote
Monitoring System had more than twice (2.4x) the probability of
survival than that of patients without remote monitoring.
The results of this study were derived from more than 260,000
patients implanted with either pacemakers or defibrillators. The
observational study showed that greater adherence to remote
monitoring enhances the well-being of patients and reduces
According to the study, patients with high adherence to remote
monitoring had a 58% reduced likelihood of mortality than patients
without using remote monitoring and a 35% reduced likelihood of
mortality than patients with low remote monitoring. Although the
results may vary according to geographic regions, socioeconomic
factors were not associated with remote monitoring use.
St. Jude Medical posted a 4.3% rise in adjusted net earnings per
share to 96 cents for the first quarter of 2014 from 92 cents a
year-ago. With this, the company beat the Zacks Consensus Estimate
by a penny and met its own guidance of 94 and 96 cents per share
for the quarter.
Revenues grew about 2.0% to $1,363 million for the quarter,
exceeding the Zacks Consensus Estimate of $1,355 million as well as
the company's own guided range of 1,280 to $1,360 million.
Unfavorable foreign currency translation reduced revenues by
roughly $25 million.
For the second quarter of 2014, St. Jude Medical expects revenues
in the range of $1,380 to $1,460 million while the company
anticipates adjusted net earnings per share to lie between 99 cents
and $1.01 for the quarter. The current Zacks Consensus Estimates
for earnings per share and revenues for the quarter are pegged at
$1.00 and $1,437 million.
For full year 2014, St. Jude Medical upgraded its revenues guidance
to the range of $5,610 to $5,760 million from the prior range of
$5,600 to $5,750 million. It also upgraded its adjusted earnings
per share guidance to $3.95-$4.00 from the prior range of
$3.94-$3.99. The current Zacks Consensus Estimates for earnings per
share and revenues for the year are pegged at $3.98 and $5,702
Currently, St. Jude retains a Zacks Rank #3 (Hold). Some
better-ranked stocks in the medical products industry that are also
worth considering include
Eagle Pharmaceuticals Inc.
). All of them retain a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
CARDICA INC (CRDC): Free Stock Analysis Report
EAGLE PHARMACT (EGRX): Free Stock Analysis
EXACTECH INC (EXAC): Free Stock Analysis Report
ST JUDE MEDICAL (STJ): Free Stock Analysis
To read this article on Zacks.com click here.